Erika Navarro-Sanchez

TL;DR: These findings reveal an unexpected degree of cross-reactivity in human antibodies against DENV and illustrate the potential for an antibody-based therapy to control severe dengue.

TL;DR: Analysis of the interactions between DV and human‐monocyte‐derived DCs at the level of virus entry shows that the DC‐specific ICAM3‐grabbing non‐integrin (DC‐SIGN) molecule, a cell‐surface, mannose‐specific, C‐type lectin, binds mosquito‐cell‐derived DVs and allows viral replication.

TL;DR: It is proposed that DC-SIGN concentrates mosquito-derived DV particles at the cell surface to allow efficient interaction with an as yet unidentified entry factor that is ultimately responsible for DV internalization and pH-dependent fusion into DCs.

TL;DR: The ability of infecting DV to counter the innate antiviral immunity might account for differences in virulence observed between viral strains.

TL;DR: Aborting infection by viral sequestration in early phagosomes would present a novel means to curb infection of enveloped virus and may constitute a prime defense system to prevent dengue virus spread shortly after the bite of the infected mosquito.